RefloDx Wins Trans Atlantic Angel Grand Prize
July 10, 2025
RefloDx competed in a field of 81 companies worldwide and won the grand prize investment from the Trans Atlantic Angel Competition 7 on June 12. The diligence team scrutinized financial projections, commercialization, regulatory, and reimbursement strategies, as well as IP review, and conducted detailed interviews with advisors, clinicians, and the RefloDx management team, including Rudy Wilcox, CEO, and Greg Critchfield, MD, MS, executive chair.
BioUtah congratulates RefloDx, which also won their category in the 2025 Entrepreneur & Investor Summit pitch competition.
Recent News
- BioUtah’s 2026 Utah Life Sciences Summit Recap
- 2026 Life Sciences Awards to be Presented at the Mayer Brown Utah Life Sciences Summit
- PROGRESS TRIAL DEMONSTRATES EDWARDS TAVR IS SUPERIOR TO CLINICAL SURVEILLANCE FOR MODERATE AS PATIENTS WITH AT-RISK FEATURES
- Denali Therapeutics Receives 2026 Prix Galien USA Award for AVLAYAH® (tividenofusp alfa-eknm) as Best Biotechnology Product
- Utah Business, Government Leaders Deepen Connections in Ireland
- Co-Diagnostics’ Joint Venture CoSara Diagnostics Announces Publication of Peer-Reviewed HPV Screening Study Using CoSara’s SARAGENE® Test
